A high-risk multiple myeloma diagnosis transformed one patient’s life in December 2020. Now enrolled in a Phase 2 clinical trial, they continue to experience persistent numbness even after four years of treatment.

A dual-antibody approach appears poised to advance treatment options for patients with extramedullary multiple myeloma. Published by Pharmacy Times, this development underscores a growing focus within oncology to refine care and address the unique challenges of this aggressive cancer subtype.